RayzeBio appoints Yi Larson to its Board of Directors

– USA, CA –  RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Yi Larson to its board of directors effective April 1, 2021.

“In my first meeting with Yi, I was immediately impressed by her intelligence and knew that I had to find a way to work with her,” said CEO, Dr. Ken Song. “In addition to her financial expertise in the life sciences sector, she has corporate and business development strategic insight and has such a great personality that you want to spend time with her.”

RayzeBio also announced the expansion of its team with the key employee hires.

About Yi Larson

Ms. Larson has a highly accomplished biotechnology career having been a Managing Director of Healthcare Investment Banking at Goldman Sachs where she worked for over 12 years, followed by CFO at Turning Point Therapeutics, and currently serving as CFO at LianBio.

“RayzeBio is clearly establishing itself as the leader in the exciting field of radiopharmaceuticals,” said Ms. Larson. “The company has impressively built an infrastructure to drive innovation in the sector. The company’s strategy and aggressive execution have attracted financial backing from a broad base of top-tier healthcare investors.”

About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020.

For more information, visit www.rayzebio.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.